Quote | Ikena Oncology Inc. (NASDAQ:IKNA)
Last: | $1.32 |
---|---|
Change Percent: | -2.27% |
Open: | $1.35 |
Close: | $1.32 |
High: | $1.38 |
Low: | $1.3 |
Volume: | 369,054 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
News | Ikena Oncology Inc. (NASDAQ:IKNA)
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2...
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalati...
Message Board Posts | Ikena Oncology Inc. (NASDAQ:IKNA)
Subject | By | Source | When |
---|---|---|---|
The now | Tartiaboy | investorshub | 05/10/2023 1:10:35 PM |
news all the way baby | crudeoil24 | investorshub | 05/05/2023 2:17:28 PM |
what do you make of this data? | crudeoil24 | investorshub | 04/17/2023 10:13:37 PM |
This is a very inactive board, but IKNA | Tartiaboy | investorshub | 01/29/2023 5:40:26 PM |
znewcar1: IKNA 29% v3,46M c5.37 f36,1M H5.37 EOD pop | znewcar1 | investorshangout | 06/25/2022 2:51:38 AM |
News, Short Squeeze, Breakout and More Instantly...
Ikena Oncology Inc. Company Name:
IKNA Stock Symbol:
NASDAQ Market:
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company")), a targeted oncology company forging new ter...
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2...
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalati...